Evidence map›Paper›PMID 41086827›Full record

ArticlePneumologie (Stuttgart, Germany)2026

[White paper on identification, information, and eligibility assessment of potential participants in lung cancer screening in Germany].

Torsten Gerriet Blum, Jens Vogel-Claussen, Hans Hoffmann, Martin Reck, Volker Harth, Anton Faron, Ingrid Dänschel, Stefan Andreas, Alexander Rupp, Rudolf Kaaks and 1 more

Erratum issuedAbstract readEnglish Abstract
In one paragraph

Article in Pneumologie (Stuttgart, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Torsten Gerriet BlumHelios Klinikum Emil von Behring GmbH, Lungenklinik Heckeshorn, BE, Deutschland, Berlin.
Jens Vogel-ClaussenMedizinische Hochschule Hannover, Institut für Diagnostische und Interventionelle Radiologie, NDS, Deutschland, Hannover.
Hans HoffmannKlinikum rechts der Isar der Technischen Universität München, Sektion Thoraxchirurgie, Bayern, Deutschland, München.
Martin ReckLungenClinic Großhansdorf GmbH, Abteilung für Onkologie, Schleswig-Holstein, Deutschland, Großhansdorf.
Volker HarthUniversitätsklinikum Hamburg-Eppendorf, Zentralinstitut für Arbeitsmedizin und maritime Medizin, HH, Deutschland, Hamburg.
Anton FaronRadiologische Allianz GbR, Thoraxdiagnostik, HH, Deutschland, Hamburg.
Ingrid DänschelHausarztpraxis Dipl. med. Ingrid Dänschel, Deutschland, Lunzenau.
Stefan AndreasLungenfachklinik Immenhausen, Deutschland, Immenhausen.
Alexander RuppPneumologische Praxis im Zentrum, Deutschland, Stuttgart.
Rudolf KaaksDeutsches Krebsforschungszentrum (DKFZ), Abteilung für Epidemiologie von Krebserkrankungen, Deutschland, Heidelberg.
Gerald Schmid-BindertUniversitätsmedizin Mannheim, Universität Heidelberg, V. Medizinische Klinik - Pneumologie, Deutschland, Mannheim.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abstract: The nationwide introduction of lung cancer screening using low-dose computed tomography (LDCT) is imminent in Germany. In contrast to other cancer screening programs, lung cancer screening follows a risk-based approach and specifically targets heavy current and former smokers aged 50 to 75 years. Following several years of pilot phases and regulatory preparation, the Federal Joint Committee (G-BA) decided in June 2025 to include this program as a regular benefit covered by statutory health insurance starting in 2026.Evidence from large international studies demonstrates a significant reduction in lung cancer mortality of approximately 20%. However, there are also risks such as overdiagnosis, unnecessary invasive procedures in false-positive findings, secondary cancers due to radiation exposure, and psychological burden.Key factors for program success include the structured involvement of qualified physicians in the identification, information, and assessment of eligibility of potential participants. Physicians in the fields of general medicine, occupational medicine, and internal medicine have been authorized after specific qualification, the latter of which includes pulmonologists - who, while not explicitly mentioned, will certainly have the closest contact with the high-risk population of smokers. This white paper provides practical information and materials for participating in lung cancer screening. It highlights the importance of dedicated interdisciplinary collaboration to detect as many lung cancer patients as possible at an early and therefore potentially curable stage.

Indexed as

Early Detection of CancerEligibility DeterminationLung NeoplasmsMass ScreeningAgedFemaleGermanyHumansMaleMiddle AgedTomography, X-Ray Computed

Identifiers

PMID41086827
PMCPMC13314295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.